Title: Inhalation Anesthesia Market size worth $1.66bn by 2024
1Inhalation Anesthesia Market size worth 1.66bn
by 2024Global Market Insights Inc.
Fuel Cell Market size worth 25.5bn by 2024
2 Key Insights from Inhalation Anesthesia Market
- Global inhalation anesthesia market size was USD
1.2 billion in 2015, and projected to reach USD
1.69 billion by 2024, slated to grow at 3.5 CAGR
from 2016 to 2024. - In terms of volume, the global anesthesia market
was 10.5 million bottles (250 ml each) in 2015,
and projected to grow at 4 CAGR to reach 14.9
million bottles by 2024. - Sevoflurane is expected to dominate the overall
revenue throughout the forecast timeline. Germany
and UK together contributed 54 to the Europe
inhalation anesthesia market share in 2015. - Maintenance anesthesia is responsible for over
85 of the global sevoflurane, desflurane and
isoflurane revenue.
3Continued...
- Sevoflurane was valued at USD 882 million in 2015
with grow expectations of 3.4 CAGR during
forecast period. - The Desflurane market is expected to grow at 2.3
CAGR and forecasted to exceed USD 300 million by
2024. - Key players include AbbVie, Halocarbon products,
Lunan Pharmaceuticals, Hikma, Piramal Healthcare,
Baxter International Inc., etc. The key strategy
adopted by these companies include mergers and
acquisitions in order to consolidate inhalation
anesthesia market share.
4U.S. Sevoflurane Market Size, by Application,
2012 - 2024 (USD Million)
5 Browse Full Market Research Report On
Inhalation Anesthesia Market _at_ http//goo.gl/XX44g
L Request for a Sample of this Research
Report _at_ https//www.gminsights.com/request-sample
/detail/704 https//www.gminsights.com/request-sa
mple/detail/49
6360 Analysis
- Product Analysis
- Sevoflurane accounted for majority of the global
inhalation anesthesia market share in 2015. This
can be attributed to quantifiable advantages over
other drugs. Sevofluranes induction and recovery
is faster than other anesthetics. Moreover, it
has low pungency and low air way irritability.
The Desflurane market was valued at over USD 280
million in 2015, and expanding at 2.3 CAGR from
2016 to 2024. - Regional Analysis
- U.S. inhalation anesthesia market share was over
80 of the North American total in 2015. This is
mainly due to the high prevalence of chronic
diseases and favorable reimbursement policies.
For instance, Medicaid reimbursed 21 of ED
visits in 2012. The reimbursement percentage
ranges from 12 in Texas to 30 in New York. - Competitive Market Share
- The major players include Baxter International
Inc., AbbVie, Piramal Healthcare, Lunan
Pharmaceuticals, Hikma, etc. These companies have
entered into strategic collaborations such as
mergers and acquisitions in order to gain share.
Piramal manufactures Sojourn, which is used for
the induction as well as maintenance of general
anesthesia in pediatric patients and adults.
7 Stay In Touch Website www.gminsights.com Soci
al Media